At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 638 enrolled
Drug / intervention
Desvenlafaxine Succinate Sustained-Release (DVS SR) +3 moredrug
Likely dose
Duloxetine 60 mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, and 1 other intervention for Depressive Disorder, Major. Completed, enrolled 638 participants across 22 sites.
Detailed Summary
The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedOct 2006
Primary CompletionSep 2007
TodayJul 2026
First PostedOct 4, 2006
Enrollment StartSep 1, 2006
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.7 years ago
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR)drug
50 mg tablet, once daily dosing for 8 weeks
Desvenlafaxine Succinate Sustained-Release (DVS SR)drug
100 mg tablet, once daily dosing for 8 weeks
Placebodrug
Matching placebo tablets and capsules, once daily dosing for 8 weeks
Duloxetine 60 mg/daydrug
60 mg capsule, once daily dosing for 8 weeks